Cargando…
Identification of drivers of mycobacterial resistance to peptidoglycan synthesis inhibitors
Beta-lactams have been excluded from tuberculosis therapy due to the intrinsic resistance of Mycobacterium tuberculosis (Mtb) to this antibiotic class, usually attributed to a potent beta-lactamase, BlaC, and to an unusually complex cell wall. In this pathogen, the peptidoglycan is cross-linked by p...
Autores principales: | Olivença, Francisco, Ferreira, Cláudia, Nunes, Alexandra, Silveiro, Cátia, Pimentel, Madalena, Gomes, João Paulo, Catalão, Maria João |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485614/ https://www.ncbi.nlm.nih.gov/pubmed/36147841 http://dx.doi.org/10.3389/fmicb.2022.985871 |
Ejemplares similares
-
CRISPRi-mediated characterization of novel anti-tuberculosis targets: Mycobacterial peptidoglycan modifications promote beta-lactam resistance and intracellular survival
por: Silveiro, Cátia, et al.
Publicado: (2023) -
Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis
por: Catalão, Maria João, et al.
Publicado: (2019) -
The Mycobacteriophage Ms6 LysB N-Terminus Displays Peptidoglycan Binding Affinity
por: Gigante, Adriano M., et al.
Publicado: (2021) -
Uncovering Beta-Lactam Susceptibility Patterns in Clinical Isolates of Mycobacterium tuberculosis through Whole-Genome Sequencing
por: Olivença, Francisco, et al.
Publicado: (2022) -
Mycobacteriophage Lysis Enzymes: Targeting the Mycobacterial Cell Envelope
por: Catalão, Maria João, et al.
Publicado: (2018)